Treatment with once-daily exenatide plus dapagliflozin and without rescue therapy was associated with clinically relevant changes in fasting plasma glucose.
For patients with diabetes, coronary artery calcium predicts cardiovascular disease and total mortality more strongly in women than men.
The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial.
Researchers investigated the association between gout, urate-lowering therapy use, and the risk of developing type 2 diabetes.
Researchers sought to determine whether triglyceride levels were independently associated with cardiovascular disease among patients with coronary artery disease and type 2 diabetes.
An intensive lifestyle intervention (ILI) may reduce the incidence of obesity-related mortality among individuals with overweight or obesity and type 2 diabetes.
The use of sodium-glucose transporter-2 inhibitors combined with metformin did not affect fracture risk in T2D.
The use of intensive lifestyle intervention for weight loss in patients with type 2 diabetes has been shown to reduce the overall severity of obstructive sleep apnea.
This study found that diabetic patients with COVID-19 had lower lymphocyte counts and hospital stays.
The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) to reduce the risk of hospitalization for heart failure or cardiovascular (CV) death in adults following an acute myocardial infarction.
